Superior Planning, LLC’s 10x Genomics TXG Stock Holding History

Superior Planning, LLC’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$52.7K	Buy	+583	New	+$34.1K	0.02%	371

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Superior Planning, LLC's TXG Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in 10x Genomics (TXG) in Q3 2026: 583 shares worth $52.7K. The stake represents 0.02% of the portfolio and ranks #371 among its holdings.

297 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

Superior Planning, LLC held 583 shares of 10x Genomics worth $52.7K as of Q3 2026.
10x Genomics was a new Superior Planning, LLC position in Q3 2026.
10x Genomics made up 0.02% of Superior Planning, LLC's portfolio in Q3 2026, its #371 holding.
297 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.